NASDAQ:DMPI - DelMar Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.62 -0.02 (-3.13 %)
(As of 07/18/2018 04:00 PM ET)
Previous Close$0.64
Today's Range$0.62 - $0.68
52-Week Range$0.61 - $2.84
Volume62,725 shs
Average Volume389,038 shs
Market Capitalization$14.80 million
P/E Ratio-0.88
Dividend YieldN/A
Beta1.47
DelMar Pharmaceuticals logoDelMar Pharmaceuticals, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients who have failed to respond to modern therapy. Its product candidate includes VAL-083, a small-molecule chemotherapeutic agent, which is in Phase III study for the treatment of recurrent glioblastoma multiforme. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical Company for the manufacture and sale of VAL-083 in China; collaboration agreement with the University of Texas MD Anderson Cancer Center; and collaboration agreement with Accurexa Inc. to develop a novel formulation for the combined local delivery of VAL-083 and temozolomide. DelMar Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Vancouver, Canada.

Receive DMPI News and Ratings via Email

Sign-up to receive the latest news and ratings for DMPI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:DMPI
CUSIPN/A
Phone604-629-5989

Debt

Debt-to-Equity RatioN/A
Current Ratio4.80
Quick Ratio4.80

Price-To-Earnings

Trailing P/E Ratio-0.88
Forward P/E Ratio-1.15
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.01 per share
Price / Book62.00

Profitability

EPS (Most Recent Fiscal Year)($0.74)
Net Income$-8,080,000.00
Net MarginsN/A
Return on Equity-397.62%
Return on Assets-102.75%

Miscellaneous

Employees15
Outstanding Shares21,930,000
Market Cap$14.80

The Truth About Cryptocurrencies

DelMar Pharmaceuticals (NASDAQ:DMPI) Frequently Asked Questions

What is DelMar Pharmaceuticals' stock symbol?

DelMar Pharmaceuticals trades on the NASDAQ under the ticker symbol "DMPI."

When did DelMar Pharmaceuticals' stock split? How did DelMar Pharmaceuticals' stock split work?

Shares of DelMar Pharmaceuticals reverse split on Friday, May 20th 2016. The 1-4 reverse split was announced on Thursday, May 19th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 19th 2016. An investor that had 100 shares of DelMar Pharmaceuticals stock prior to the reverse split would have 25 shares after the split.

How were DelMar Pharmaceuticals' earnings last quarter?

DelMar Pharmaceuticals Inc (NASDAQ:DMPI) released its quarterly earnings results on Tuesday, May, 15th. The company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by $0.03. View DelMar Pharmaceuticals' Earnings History.

When is DelMar Pharmaceuticals' next earnings date?

DelMar Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, August, 30th 2018. View Earnings Estimates for DelMar Pharmaceuticals.

What price target have analysts set for DMPI?

3 brokerages have issued 1 year target prices for DelMar Pharmaceuticals' shares. Their predictions range from $12.00 to $12.00. On average, they anticipate DelMar Pharmaceuticals' stock price to reach $12.00 in the next year. This suggests a possible upside of 1,835.5% from the stock's current price. View Analyst Ratings for DelMar Pharmaceuticals.

What is the consensus analysts' recommendation for DelMar Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DelMar Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about DelMar Pharmaceuticals stock?

Here are some recent quotes from research analysts about DelMar Pharmaceuticals stock:
  • 1. HC Wainwright analysts commented, "Ovarian Cancer Role for VAL-083; Reiterate Buy Stock Data 10/13/2017 Price $0.88 Exchange NASDAQ Price Target $12.00 52-Week High $5.77 52-Week Low $0.80 Enterprise Value (M) $12.4 Market Cap (M) $19 Public Market Float (M) 19.3 Shares Outstanding (M) 21.6 3 Month Avg Volume 959,521 Short Interest (M) 0.35 Balance Sheet Metrics Cash (M) $6.59 Total Debt (M) $0.00 Total Cash/Share $0.31 Book Value/Share $(0.09) EPS Diluted Full Year – Jun 2016A 2017A 2018E 1Q (0.15) (0.23) (0.17) 2Q (0.24) (0.13) (0.16) 3Q (0.10) (0.18) (0.14) 4Q (0.31) (0.20) (0.12) FY (0.81) (0.74) (0.57) 6 5 4 3 2 1 0 OCT- 16 FEB- 17 J UN- 17 OCT- 17 40 30 20 10 0 Vol. (mil) Price Continuing coverage under the name H.C. Wainwright & Co. with a Buy rating. Effective October 5, 2017, research in the above titled name will now be published under H.C. Wainwright & Co. and no longer distributed in conjunction with ‘Rodman & Renshaw, a unit of H.C." (10/16/2017)
  • 2. Maxim Group analysts commented, "Delmar announced news of another Phase II trial (biomarker driven), N=20-30 in newly diagnosed MGMT-unmethylated glioblastoma multiforme (GBM). The trial will be funded by Guangxi Wuzhou Pharmaceutical Group Co. (private). Management states that data is expected 9-15 months from the time the trial begins." (9/11/2017)

Who are some of DelMar Pharmaceuticals' key competitors?

Who are DelMar Pharmaceuticals' key executives?

DelMar Pharmaceuticals' management team includes the folowing people:
  • Mr. Saiid Zarrabian B.Sc., MBA, Pres, CEO & Director (Age 65)
  • Mr. Jeffrey A. Bacha, Founder (Age 50)
  • Dr. Dennis M. Brown, Co-Founder & Chief Scientific Officer (Age 69)
  • Mr. Scott Praill, CFO & Sec. (Age 51)
  • Dr. Victor Levin M.D., Advisor

Has DelMar Pharmaceuticals been receiving favorable news coverage?

News headlines about DMPI stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. DelMar Pharmaceuticals earned a media sentiment score of 0.24 on Accern's scale. They also assigned news articles about the company an impact score of 48.05 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

How do I buy shares of DelMar Pharmaceuticals?

Shares of DMPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is DelMar Pharmaceuticals' stock price today?

One share of DMPI stock can currently be purchased for approximately $0.62.

How big of a company is DelMar Pharmaceuticals?

DelMar Pharmaceuticals has a market capitalization of $14.80 million. The company earns $-8,080,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis. DelMar Pharmaceuticals employs 15 workers across the globe.

How can I contact DelMar Pharmaceuticals?

DelMar Pharmaceuticals' mailing address is SUITE 720-999 WEST BROADWAY, VANCOUVER A1, V5Z 1K5. The company can be reached via phone at 604-629-5989 or via email at [email protected]


MarketBeat Community Rating for DelMar Pharmaceuticals (NASDAQ DMPI)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  130 (Vote Outperform)
Underperform Votes:  88 (Vote Underperform)
Total Votes:  218
MarketBeat's community ratings are surveys of what our community members think about DelMar Pharmaceuticals and other stocks. Vote "Outperform" if you believe DMPI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DMPI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/18/2018 by MarketBeat.com Staff

Featured Article: Earnings Per Share

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.